相关实验视频

Updated: May 31, 2025

Visualization of Metabolites Identified in the Spatial Metabolome of Traditional Chinese Medicine Using DESI-MSI

Visualization of Metabolites Identified in the Spatial Metabolome of Traditional Chinese Medicine Using DESI-MSI

Published on: December 16, 2022

关于Silybum marianum代谢物的初步数据:全面的表征,抗氧化剂,抗糖尿病,抗微生物活性,LC-MS/MS分析,以及预测的ADMET分析

Sabrina Lekmine¹, Ouided Benslama², Mohammad Shamsul Ola³

¹Biotechnology, Water, Environment and Health Laboratory, Abbes Laghrour University, Khenchela 40000, Algeria.

|January 24, 2025

概括

微波增强的Silybum marianum提取物显示出强大的抗氧化剂,抗糖尿病和抗菌性质. 这些发现表明它在各种健康应用中具有显著的治疗潜力.

科学领域:

植物化学植物化学
药理学药理学是指药理学的学科.
自然产品自然产品

背景情况:

马里安 (Silybum marianum) 是一种具有长期药用历史的植物.
微波增强提取提供了一种有效的方法来隔离生物活性化合物.
了解S. marianum提取物的治疗潜力对于开发新疗法至关重要.

研究的目的:

评估S. marianum提取物的抗氧化,抗糖尿病和抗微生物活性.
为了识别和量化提取物中的关键代谢物.
评估已识别的化合物的in silico药物相似性和安全性.

主要方法:

微波增强提取,然后进行LC-MS/MS代谢物分析.
总和黄的光谱测量量量化.
在体外抗氧化剂 (DPPH,ABTS,CUPRAC,Phenanthroline,FRAP),抗糖尿病药物 (α-葡萄糖酶,α-氨基酶抑制) 和抗菌剂的测定.
在基中,ADMET和主要代谢物的药物相似性预测.

主要成果:

提取物含有高水平的基 (251.2 mg GAE/g) 和黄 (125.1 mg QE/g),以及33种已识别的代谢物.
在多项测定中观察到显著的抗氧化活性 (例如,ABTS IC50:7.2μg/mL).
证明了强大的抗糖尿病作用 (α-葡萄糖酶IC50:18.1μg/mL) 和广泛的抗菌活性.
在基分析表明吸收,新陈代谢,分泌和毒性概况有利.

结论:

青 (Silybum marianum) 提取物具有显著的抗氧化,抗糖尿病和抗微生物活性.
已识别的代谢物及其生物活动支持了植物的治疗潜力.
提取物是各种健康状况中的治疗和预防应用的有希望的候选者.

关键词:

这种植物叫Silybum marianum.抗微生物药物是一种抗菌药物.抗氧化剂是一种抗氧化剂.酶抑制的酶抑制剂微波增强提取方式的微波提取.

更多相关视频

Investigation of Xenobiotics Metabolism In Salix alba Leaves via Mass Spectrometry Imaging

Investigation of Xenobiotics Metabolism In Salix alba Leaves via Mass Spectrometry Imaging

Published on: June 15, 2020

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

相关概念视频

Drug Metabolism: Phase II Reactions

Drug Metabolism: Phase II Reactions

Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...

Drug Metabolism: Phase I Reactions

Drug Metabolism: Phase I Reactions

A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...

Drug Biotransformation: Overview

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...